P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Application of several cell cycle checkpoint regulators seem to be promising in various experimental models including pancreatic cancer, and they are being evaluated in Phase I-II clinical trials. Among these compounds, mimosine, a plant-derived amino acid has shown an antineoplastic effect on human lung or pancreatic cancer xenografts in addition to cell cycle arrest in the late G1 phase. In the present study, immunosuppressed CBA mice bearing subcutaneously growing human ductal pancreatic adenocarcinomas were treated with 30 mg/kg L-mimosine for 34 days. The treatment resulted in retardation of tumor growth, accompanied by a significantly diminished proliferative activity (22.6% ± 1.7% Ki-67 positivity vs. 29.9% ± 1.1% in controls, mean ± SEM, P <0.007) and an increased apoptotic rate (14.5 ± 1.1 apoptotic cells/mm2 vs. 3.8 ± 0.4/mm2 in the controls, P <0.0001). The immunohistochemical expression of the multidrug resistance gene (MDR1)-encoded P-glycoprotein (p170) was studied. The parental and the untreated tumors did not express p170 protein, but in the mimosine-treated samples 30 to 60% of the carcinoma cells displayed a linear, membrane-bound positivity. The results indicate that P-glycoprotein is inducible by a cell cycle regulator, creating an acquired resistant phenotype.

Original languageEnglish
Pages (from-to)164-169
Number of pages6
JournalPathology and Oncology Research
Volume11
Issue number3
Publication statusPublished - 2005

Fingerprint

Mimosine
P-Glycoprotein
Pancreatic Neoplasms
Heterografts
Cell Cycle
Cell Cycle Checkpoints
MDR Genes
Inbred CBA Mouse
Phase II Clinical Trials
Clinical Trials, Phase I
G1 Phase
Antineoplastic Agents
Lung Neoplasms
Neoplasms
Adenocarcinoma
Theoretical Models
Carcinoma
Phenotype
Amino Acids
Membranes

Keywords

  • Human tumors
  • Mimosine
  • P-glycoprotein
  • Pancreatic cancer
  • Xenografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{8665a61f22f2434494f87f46b889867b,
title = "P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine",
abstract = "Application of several cell cycle checkpoint regulators seem to be promising in various experimental models including pancreatic cancer, and they are being evaluated in Phase I-II clinical trials. Among these compounds, mimosine, a plant-derived amino acid has shown an antineoplastic effect on human lung or pancreatic cancer xenografts in addition to cell cycle arrest in the late G1 phase. In the present study, immunosuppressed CBA mice bearing subcutaneously growing human ductal pancreatic adenocarcinomas were treated with 30 mg/kg L-mimosine for 34 days. The treatment resulted in retardation of tumor growth, accompanied by a significantly diminished proliferative activity (22.6{\%} ± 1.7{\%} Ki-67 positivity vs. 29.9{\%} ± 1.1{\%} in controls, mean ± SEM, P <0.007) and an increased apoptotic rate (14.5 ± 1.1 apoptotic cells/mm2 vs. 3.8 ± 0.4/mm2 in the controls, P <0.0001). The immunohistochemical expression of the multidrug resistance gene (MDR1)-encoded P-glycoprotein (p170) was studied. The parental and the untreated tumors did not express p170 protein, but in the mimosine-treated samples 30 to 60{\%} of the carcinoma cells displayed a linear, membrane-bound positivity. The results indicate that P-glycoprotein is inducible by a cell cycle regulator, creating an acquired resistant phenotype.",
keywords = "Human tumors, Mimosine, P-glycoprotein, Pancreatic cancer, Xenografts",
author = "A. Zalatnai",
year = "2005",
language = "English",
volume = "11",
pages = "164--169",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine

AU - Zalatnai, A.

PY - 2005

Y1 - 2005

N2 - Application of several cell cycle checkpoint regulators seem to be promising in various experimental models including pancreatic cancer, and they are being evaluated in Phase I-II clinical trials. Among these compounds, mimosine, a plant-derived amino acid has shown an antineoplastic effect on human lung or pancreatic cancer xenografts in addition to cell cycle arrest in the late G1 phase. In the present study, immunosuppressed CBA mice bearing subcutaneously growing human ductal pancreatic adenocarcinomas were treated with 30 mg/kg L-mimosine for 34 days. The treatment resulted in retardation of tumor growth, accompanied by a significantly diminished proliferative activity (22.6% ± 1.7% Ki-67 positivity vs. 29.9% ± 1.1% in controls, mean ± SEM, P <0.007) and an increased apoptotic rate (14.5 ± 1.1 apoptotic cells/mm2 vs. 3.8 ± 0.4/mm2 in the controls, P <0.0001). The immunohistochemical expression of the multidrug resistance gene (MDR1)-encoded P-glycoprotein (p170) was studied. The parental and the untreated tumors did not express p170 protein, but in the mimosine-treated samples 30 to 60% of the carcinoma cells displayed a linear, membrane-bound positivity. The results indicate that P-glycoprotein is inducible by a cell cycle regulator, creating an acquired resistant phenotype.

AB - Application of several cell cycle checkpoint regulators seem to be promising in various experimental models including pancreatic cancer, and they are being evaluated in Phase I-II clinical trials. Among these compounds, mimosine, a plant-derived amino acid has shown an antineoplastic effect on human lung or pancreatic cancer xenografts in addition to cell cycle arrest in the late G1 phase. In the present study, immunosuppressed CBA mice bearing subcutaneously growing human ductal pancreatic adenocarcinomas were treated with 30 mg/kg L-mimosine for 34 days. The treatment resulted in retardation of tumor growth, accompanied by a significantly diminished proliferative activity (22.6% ± 1.7% Ki-67 positivity vs. 29.9% ± 1.1% in controls, mean ± SEM, P <0.007) and an increased apoptotic rate (14.5 ± 1.1 apoptotic cells/mm2 vs. 3.8 ± 0.4/mm2 in the controls, P <0.0001). The immunohistochemical expression of the multidrug resistance gene (MDR1)-encoded P-glycoprotein (p170) was studied. The parental and the untreated tumors did not express p170 protein, but in the mimosine-treated samples 30 to 60% of the carcinoma cells displayed a linear, membrane-bound positivity. The results indicate that P-glycoprotein is inducible by a cell cycle regulator, creating an acquired resistant phenotype.

KW - Human tumors

KW - Mimosine

KW - P-glycoprotein

KW - Pancreatic cancer

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=27644510512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644510512&partnerID=8YFLogxK

M3 - Article

C2 - 16195770

AN - SCOPUS:27644510512

VL - 11

SP - 164

EP - 169

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -